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Cytopenia and delayed immune reconstitution with acute graft-versus-host disease (aGVHD) indicate a poor
prognosis. However, how donor-derived cell hematopoiesis is impaired in aGVHD is not well understood. We
addressed this issue by studying the kinetics of hematopoiesis and the functions of hematopoietic stem and
progenitor cells in an aGVHD model with haplo-MHCematched murine bone marrow transplantation.
Although hematopoiesis was progressively suppressed during aGVHD, the hematopoietic regenerative po-
tential of donor-derived hematopoietic stem cells remains intact. There was a dramatic reduction in primitive
hematopoietic cells and a defect in the ability of these cells to generate common myeloid progenitors (CMPs)
and megakaryocyte/erythrocyte progenitors (MEPs). These effects were observed along with a concomitant
increase in granulocyte/macrophage progenitors, suggesting that differentiation into MEPs is blocked during
aGVHD. Interestingly, cyclosporine A was able to partially reverse the hematopoietic suppression as well as
the differentiation blockage of CMPs. These data provide new insights into the pathogenesis of aGVHD and
may improve the clinical management of aGVHD.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
In patients with graft-versus-host disease (GVHD), cyto-
penia is considered one of the most consistent and strongest
predictive factors for poor survival [1]. Prolonged thrombo-
cytopenia may require platelet transfusion for the manage-
ment and prevention of severe bleeding. This condition may
also impact treatment outcomes and prognosis [2-5]. How-
ever, the exact mechanisms responsible for cytopenia in
patients with GVHD are poorly deﬁned.
Hematopoietic stem cells (HSCs) are traditionally deﬁned
as cells that are able to produce all types of blood cells in a
speciﬁc bone marrow (BM) microenvironment. Some key
molecules that regulate the self-renewal, proliferation, and
differentiation of HSCs during steady-state hematopoiesis
have been identiﬁed using knock-outmousemodels and bone
marrow transplantation (BMT)-induced stress [6,7]. How-
ever, how the HSC compartment responds to pathologicaledgments on page 1299.
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14.05.009conditions is still poorly understood. In a lipopolysaccharide-
induced sepsis model, the expansion of the HSC pool and
neutrophil depletion were observed by Rodriguez et al. [8].
The self-renewal ability of HSCs was signiﬁcantly impaired,
which led to insufﬁcient myeloid cell generation to ﬁght
sepsis. With chronic infection, Baldridge et al. [9] found that
an increased proportion of proliferative long-term repopu-
lating HSCs was caused by IFN-g. Our previous study showed
that the effects of the leukemic environment on HSCs and
hematopoietic progenitor cells (HPCs)were distinct in that the
repopulation potential of HSCs is preserved, whereas HPCs
were exhausted [10]. The results of several mouse studies
have shown that the number of donor-derived blood cells is
reduced and that Fas-mediated apoptosis is involved in the
process [11-14]. However, a systemic investigation of the ki-
netics of donor-derived hematopoietic stem and progenitor
cells (HSPCs) in acute GVHD (aGVHD) hosts is lacking.
In the current study, using a haplo-MHCematched murine
BMT model that recapitulates the BM failure process in hosts
with aGVHD, we documented the kinetics of donor-derived
HSPCs during aGVHD and explored the underlying mecha-
nisms. Furthermore, based on the current management of
aGVHD in the clinic, we used cyclosporine A (CsA) to partiallyTransplantation.
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blockage of common myeloid progenitors (CMPs).
METHODS
Mice
C57BL/6J (CD45.2þ) and BALB/C (CD45.2þ) mice were purchased from
the Institution of Zoology of the Chinese Scientiﬁc Academy (Shanghai,
China). B6.SJL-PtprcaPepcb/BoyJ mice (B6.SJL, CD45.1þ) were obtained from
Dr. Tao Cheng (State Key Laboratory of Experimental Hematology, Tianjin,
China) and maintained in our animal facility. CB6F1 mice (CD45.2þ) were
the F1 generation of male C57BL/6J mated to female BALB/C mice. All mice
were maintained in a speciﬁc pathogen-free condition. All animal protocols
were approved by the Institutional Animal Care and Use Committees of all
institutions participating in this study.
BMT Procedures and the Induction of aGVHD
Lethally irradiated (8.0 Gy) female CB6F1 recipients (CD45.2þ, 6 to
8 weeks old) were intravenously injected with 5  106 BM nucleated cells
(BMNCs) from male B6.SJL mice (CD45.1þ, 6 to 8 weeks old) along with
6  107 spleen cells from either female C57BL/6 mice (CD45.2þ, 6 to 8 weeks
old, the aGVHD group) or female CB6F1 mice (CD45.2þ, 6 to 8 weeks old, the
control group) 4 to 6 hours after irradiation, as indicated in Figure 1A. We
tested various amounts of splenocytes for transplantation (1 to 8  107) and
found 6  107 to be the ideal amount for the induction of aGVHD.
The recipient mice were killed every week unless otherwise speciﬁed.
Hematopoietic reconstitution by the donor-derived cells was monitored. The
severity of GVHD was assessed with a clinical GVHD scoring system as ﬁrst
described by Cooke et al. [15]. The following 5 clinical parameters were scored
3 times a week on a scale from 0 to 2: weight loss, posture, activity, fur
texture, and skin integrity. The clinical GVHD index was generated by sum-
ming the 5 criteria scores (0 to 10). Survival was monitored on a daily basis.
Flow Cytometry
Mouse BM cells were obtained by ﬂushing ilia, femurs, and tibias as
previously described [16]. The immunophenotypes of murine long-term HSCs
(LT-HSCs; CD34Flk2Linc-KitþSca-1þ, CD34Flk2LKS), short-term HSCs
(ST-HSCs; CD34þFlk2Lin-c-KitþSca-1þ, CD34þFlk2LKS), multipotential
progenitors (MPPs; CD34þFlk2þLin-c-KitþSca-1þ, CD34þFlk2þLKS), and
HPCs (Linc-KitþSca-1, LKS, including CMPs [CD34þCD16/32loLin-c-KitþSca-
1-,CD34þCD16/32loLKS], common lymphoid progenitors [CLPs; CD34þIL-
7aþLin-c-KitloSca-1lo], granulocyte/macrophage progenitors [GMPs;
CD34þCD16/32hiLin-c-KitþSca-1, CD34þCD16/32hiLKS], and megakaryocyte/
erythrocyte progenitors [MEPs; CD34CD16/32loLin-c-KitþSca-1, CD34CD16/
32loLKS]) [17-19] were used to quantify these different cell types within the
donor-derived cell populations. All antibodies were purchased from eBio-
science (San Diego, CA) unless otherwise noted.
For the detection of donor-derived HSPCs, the following antibodies were
used: a mixture of lineage-speciﬁc antibodies (biotin anti-CD3, CD4, CD8,
B220, Gr-1, Mac-1, and Ter-119), PE-Cy7 anti-Sca-1, PE anti-Flk2 or PE anti-
CD16/32, APC anti-c-Kit, PE-Cy5.5 anti-CD45.1, FITCanti-CD34, and
streptavidin-conjugated APC-Cy7. For the detection of T cells, B cells,
monocytes, and granulocytes, PE anti-CD3, FITC anti-B220, APC anti-Mac-1,
PE-Cy7 anti-Gr-1, and PE-Cy5.5 anti-CD45.1 were used.
For HSPCs isolation, c-Kitþ cells were enriched using CD117-conjugated
magnetic microbeads (Miltenyi Biotec, Auburn, CA) according to the man-
ufacturer’s instructions. The enriched cells were stained with antibodies as
described above, and then the CD45.1þ CMPs were directly sorted into
different tubes and lysed for gene expression analysis. For donor-derived
hematopoietic cell (CD45.1þ) sorting, BM cells from mice in the aGVHD or
control groups were pooled and stained with FITC anti-CD45.1 and PE anti-
CD45.2 antibodies (eBioscience, San Diego, CA). A FACS AriaII (BD Bio-
sciences) was used for sorting.
Cell Cycle and Apoptosis Analyses
In this study, we deﬁned murine HSCs as LinSca1þCD150þcells, MPPs
as LinSca1þcells, and HPCs as Lin cells. We did not include c-kit in the
immunophenotypes because it is undetectable shortly after BMT [20]. For
cell cycle analysis, prestained cells were stained with 10 mg/mL Hoechst-
33342 (Sigma Aldrich, St. Louis, MO) and FITC anti-Ki67 (BD Biosciences).
The level of apoptosis was measured by labeling BM cells with Annexin-V
and the DNA dye 7-aminoactinomycin D (7-AAD, BD Biosciences) in com-
bination with cell surface markers.
In Vitro Clonal Assay
Two weeks after BMT, CD45.1þ cells were sorted for an in vitro clonal
assay and placed in M3434 methylcellulose medium (Stem Cell Technolo-
gies, Vancouver, BC, Canada) in 24-well plates with a volume of .5 mL at adensity of 2  104 cells/mL with 4 replicate wells. At day 10, the colonies
were counted under an inverted microscope and recorded as the number of
colonies for the speciﬁc lineage.
Competitive BMT
A competitive BMT model was used as described previously [10,16]. A
total of 2  106 sorted CD45.1þ cells along with an equal number of CD45.2þ
BMNCs isolated from healthy nontransplanted donor (competitive cells)
were cotransplanted into lethally irradiated (8.0 Gy) female CB6F1 re-
cipients (n ¼ 20 per group, 6 to 8 weeks old). The chimerism of the pe-
ripheral blood (PB) was monitored monthly for up to 6 months. The relative
contributions of the donor-derived cells (CD45.1þ) and the competitive cells
(CD45.2þ) to hematopoietic reconstitution were measured by ﬂow cytom-
etry using FITC anti-CD45.1 and PE anti-CD45.2 antibodies.
Cytokine Proﬁling
At the early stage after BMT (16 hours and day 3), serum samples were
collected from at least 4 mice per group. A Milliplex MAP immunoassay
(Merck Millipore, Billerica, MA) was used to determine the cytokine proﬁle
according to themanufacturer’s instructions. The levels of mouse IL-1a, IL-2,
and IFN-g were examined and reported in units of pg/mL.
CsA Administration
CsA (Novartis PharmaSchweiz AG, Switzerland) diluted in 200 mL PBS
was administered intraperitoneally daily to aGVHDmice from day 0 to day 28
at a dose of 10 mg/kg/day.
Quantitative Reverse Transcriptase PCR
At 2 weeks after BMT, CD45.1þ LKS cells were sorted directly into RNeasy
Lysis Buffer (Buffer RLT, Qiagen,Denmark) containingb-mercaptoethanol. Total
RNA was extracted with the RNeasy Mini Kit (Qiagen, Denmark). cDNA was
synthesized using Improm-II reverse transcriptase (Promega, Madison, WI).
Real-time PCR was conducted with SYBR Green Master Mix (Roche, Indian-
apolis, IN). All the primer sequences are listed in Supplemental Table 1.
Statistical Analysis
GraphPad Prism 5.0 (San Diego, CA) was used to analyze the results and
create graphs. All comparisons represent 2-tailed unpaired t-test analyses
unless otherwise speciﬁed. The ﬂow cytometry data were analyzed with
FlowJo Version 7.6.1 software (TreeStar, Costa Mesa, CA).
RESULTS
Donor-Derived Hematopoiesis Is Suppressed in aGVHD
Hosts
A haplo-MHCematched BMT mouse model was used in
the present study to recapitulate aGVHD after allogeneic
(allo)-BMT in humans [21]. CD3þ cells accounted for
approximately 30% of transplanted spleen cells (data not
shown). All mice in the aGVHD group developed typical
aGVHD symptoms and died within 28 days after allo-BMT
(Figure 1B). The body weight began to decrease at day 3 in
both groups. From day 13 to day 27, the body weight in the
aGVHD group was signiﬁcantly lower than that in the BMT
control group (Figure 1C). Histological examinations of the
liver, intestines, lungs, and spleen revealed lymphocyte
inﬁltration and inﬂammation in the aGVHD group but not in
the control group (Figure 1D). The average aGVHD score was
2.7 at day 14 after allo-BMT (data not shown). By day 21, all
surviving recipients in the aGVHD group developed severe
cytopenia (Figure 1E-G), with a 4.4-fold reduction in the
WBC count (P < .0001), a 1.5-fold reduction in hemoglobin
(P ¼ .0008), and a 2.3-fold reduction in the platelet count
(P ¼ .0377) compared with the control group.
To quantify the contribution of donor-derived hemato-
poietic cells, we monitored the kinetics of the hematopoiesis
of donor-derived hematopoietic cells (CD45.1þ) in both the
PB and BM weekly after BMT. Both the total number and the
frequency of CD45.1þ cells in the aGVHD BMwere lower than
those in the controls (Figure 2A-C). At day 14 after BMT, the
total number of BM cells in the aGVHD mice was approxi-
mately 44% of that in the control mice. The average
Figure 1. Establishment of amurine aGVHDmodel. Amurine haplo-MHCematched BMTmodel was established by transplanting 5106 BMNCs (CD45.1þ) from B6.SJL
mice into lethally irradiated recipients (8.0Gy, CB6F1, CD45.2þ) alongwith 6107 spleen cells fromeither C57BL/6mice (CD45.2þ, 6-8weeks old, aGVHDgroup)or CB6F1
mice (CD45.2þ, 6-8 weeks old, the control group) 4-6 hours after irradiation. CD45.1þ donor-derived hematopoiesis was analyzed, and these cells were sorted by ﬂow
cytometry at the indicated time points (A). Mice in the control group had signiﬁcantly longer survival than the mice in the aGVHD group according to the Kaplan-Meier
analysis, P < .0001, n¼ 16 in each group (B). (C) Body weights of the 2 groups. (D) Histological changes associated with aGVHD in the spleen, intestines, liver, and lungs
(100 magniﬁcation). (E) WBC count, (F) hemoglobin level, and (G) platelet count in the PB are shown. Data are expressed as mean  standard error (SE). *P < .05;
**P < .01. These results are representative of at least 3 independent experiments and greater than 5 mice in the aGVHD and control groups.
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57.78%  4.10% at day 14 and 54.7%  1.71% at day 21 after
allo-BMT, signiﬁcantly lower than the percentages in the
control BM, which were stable at approximately 98.95% at
day 14 and 91.88% at day 21, respectively (P < .05). A similar
trend was observed in the PB.
B lymphopenia in aGVHD has been reported in several
clinical and experimental studies [22-27]. The evaluation of
mature subsets also showed that B lymphopoiesis was
particularly affected. At day 18 after BMT, the percentage of B
lymphocytes was 0.41%  .15% in the aGVHD group versus
7.81%  .65% in the control group (P ¼ .0004, Figure 2D). The
frequency of T cells was lower in aGVHD group when
comparedwith control mice, but without statistical difference
(Figure 2E). Furthermore, the frequencies of granulocytes and
monocytes were close to or even higher than those in the
control mice at the later stage of aGVHD development. Those
cell lineages even exhibited signs of recovery in the presence
of aGVHD (Figure 2F-G). These data are consistent with those
in a previous report [28]. Further experiments revealed that
the differentiation of the B cell lineage was blocked at the
stage of pro-B cells (CD19þc-KitþIgM, Figure 2H-J). The
evaluation of apoptosis within the CD45.1þB220þ population
showed a higher percentage of Annexin Vepositive cells in
aGVHD mice at day 14 and day 21 after allo-BMT (Figure 2K).
However, the level of B cell apoptosis (3% to 6%) in the aGVHD
mice suggested that apoptosis only partially accounted for the
reduction in B lymphocytes in the aGVHD hosts. Collectively,
these data demonstrate that in the context of BM suppression
by aGVHD, B lymphopoiesiswas particularly affected, whereas
no signiﬁcant changes were observed in the frequencies of
myeloid cells.Hematopoietic Suppression Occurs at the Stem
and Progenitor Cell Levels, but the Hematopoietic
Regenerative Potential of Donor-Derived HSCs
Remains Intact in aGVHD Hosts
To determine whether the suppression of donor-derived
hematopoietic cells (CD45.1þ) in the aGVHD BM was due to
a negative impact on HSPCs, we quantiﬁed the frequencies
and absolute numbers of HSCs and HPCs (Figure 3A,B). At day
14, absolute numbers of LKS, LKS, and Lin cells were lower
in the mice with aGVHD than in the controls. Although the
total numbers and frequencies of donor-derived cells
(CD45.1þ cells) in the aGVHD BM were signiﬁcantly lower
than those in the control BM, a higher frequency of LKS cells,
a cell subset greatly enriched for HSPCs, was observed
among donor-derived hematopoietic cells. The frequencies
of LT-HSCs, ST-HSCs, and MPPs were therefore increased
(Figure 3C,D). The input (CD45.1þCD34Flk2LKS) and
output (CD45.1þ BMNCs and CD45.1þ LKS) cells harvested at
day 14 were measured. The yield of LKS cells per initial
CD34Flk2LKS cell in the aGVHD hosts was 1.5 times lower
than that in the controls (Supplemental Table 2). An inde-
pendent quantitation of HSCs using the signaling lympho-
cytic activation molecule markers further conﬁrmed theFigure 2. Suppression of donor-derived hematopoietic regeneration during aGVHD
matopoietic cells (CD45.1þ) in both BM and PB were monitored from day 7 to day
granulocytes (Mac-1þGr-1þ), and monocytes (Mac-1þGr-1) in the PB were measured
harvested every 3 days to evaluate the frequencies of immature and mature B cells
(B220þCD19þc-KitþIgM) (J). The results are shown as mean  SE. *P < .05; **P < .01
with similar results. The proportion of apoptotic CD45.1þB cells (Annexin Vþ/7-AAD)
The results are shown as mean  SE. *P < .05; **P < .01 (n ¼ 6-16 per each group, t-signiﬁcant inhibition of HSPC regeneration in the aGVHD
hosts (Supplemental Figure 1A-D).
HSCs progressively differentiate into progenitor cells,
which, in turn, generate various mature blood cell lineages.
Our results showed that the frequencies of CMPs and CLPs
were decreased in mice with aGVHD (Figure 3E), and the
frequency of MEPs was also signiﬁcantly lower in the aGVHD
BM than in the control BM, whereas the frequency of GMP
was increased (Figure 3F,G). The increased GMP frequency
was consistent with the increased frequencies of the Mac-
1þGr-1þ and Mac-1þGr-1 populations in PB, as described
above (Figure 2F,G). The suppression of CLPs during aGVHD
may contribute to the barely detectable level of B lympho-
cytes in the PB (Figure 2D).
At day 14 after BMT, CD45.1þ cells from the aGVHD and
control groups were harvested for an in vitro clonal func-
tional assay. The donor-derived CD45.1þ cells from the
aGVHD mice had a higher capacity to generate colonies
from the committed progenitors (Figure 4A). Together
with the phenotypic analysis, these data provide func-
tional evidence for the increased frequencies of HPCs as
measured by the CFC (colony-forming cell) assay during
aGVHD development.
We next examined the repopulating ability of hematopoi-
etic cells from aGVHD hosts in a new host by competitive
transplantation. Engraftment analysis based on PB chimerism
(CD45.1 versus CD45.2) was performed monthly after trans-
plantation. The level of CD45.1þ cells from the aGVHD hosts
increased 1 month after cBMT. Six months after cBMT, the
engraftment of CD45.1þ cells from the aGVHD hosts was 2
times greater than that from the control group (19.37% versus
8.89%; P ¼ .0171; Figure 4B). Of note, the frequency of LT-HSCs
in 2  106 hematopoietic cells harvested from aGVHD hosts
was almost 2 times higher than that in cells harvested from the
control group (Figure 3C). These data indicate that therewas no
apparent defect in the repopulation potential of donor-derived
HSCs from the aGVHD environment. A multilineage analysis of
PB from cBMT recipients revealed that the HSCs in the aGVHD
environment maintained their ability to differentiate into both
myeloid and lymphoid lineages at a level comparable with that
of the control group (Figure 4C).Donor-Derived Stem/Progenitor Cells in the aGVHD Hosts
Tend to Be More Quiescent without a Homing Defect
To address the mechanism that caused the absolute
number of donor-derived (CD45.1þ) cells to be signiﬁcantly
decreased in the aGVHD BM, we examined whether this
reduction is related to the insufﬁcient homing of donor-
derived cells or changes in cell proliferation or apoptosis.
We ﬁrst evaluated the homing rate by examining the per-
centage of donor-derived (CD45.1þ) cells in the BM 16 hours
after BMT as previously described with minor modiﬁcations
[29]. There were no signiﬁcant differences in the homing
efﬁciency between the 2 groups (Figure 5A). We further
quantiﬁed the homed stem/progenitor cells, and the fre-
quencies of primitive cells among CD45.1þ cells were notdevelopment. Total BM cellularity and the percentage of donor-derived he-
21 after BMT (A, B, and C). The frequencies of B cells (B220þ), T cells (CD3þ),
every 3 days after BMT (D, E, F, and G, respectively). After BMT, BMNCs were
(B220þIgMþ) (H), B-cell precursors (B220þIgM) (I), and a class of pro-B cells
(n ¼ 3 for each time point, t-test). The data shown are from 1 of 3 experiments
in aGVHD BM or control BM was measured at day 14 and day 21 after BMT (K).
test). Data shown are representative of 4 experiments with similar results.
Figure 3. Kineticsof thehematopoiesis ofdonor-derivedHSCs/HPCs inaGVHDmice. The frequenciesandabsolutenumbersof LKS, LKS, andLin cells amongCD45.1þBMNCs
atday14afterBMT(AandB). Flowcytometric analysisof LT-HSCs, ST-HSCs, andMPPsamongCD45.1þBMNCsat day14afterBMT (C). Representativedata for LT-HSCs, ST-HSCs,
andMPPs among the CD45.1þ BMNCs from aGVHD or control BM at day 14 after BMT (D). The frequencies of more-committed progenitors, including CMPs, CLPs, GMPs, and
MEPs, in the donor-derived BMNCs (CD45.1þ) (E and F). Representative data for CMPs, GMPs, andMEPs among the CD45.1þ BMNCs from aGVHD or control BMat day 14 after
BMT (G). The results are shown as mean  SE. *P < .05; **P < .01 (n ¼ 7-21 per each group, t-test). The data shown are representative of 3 experiments with similar results.
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Figure 2).
It is well known that quiescence is associated with
the quality of stem cells [16,30]. The quiescent fraction
of donor-derived primitive cells in the cell cycle was
examined using costaining with anti-Ki67 and the DNA
dye Hoechst 33342. A signiﬁcantly larger fraction of
CD45.1þLinSca1þCD150þcells from the aGVHD BM were in
G0 phase, suggesting the aGVHD BM is able to keep the HSCs
in a more quiescent state (Figure 5B, Supplemental Figure 3).
Interestingly, the percentage of apoptotic HSCs was almost
equivalent between the aGVHD BM and the control BMwhen
examined by Annexin V and 7-AAD staining (7.9%  1.92%
versus 6.65%  1.06%, P ¼ .66), and there was no signiﬁcant
difference in the apoptosis rates of HPC and MPP subsets as
well (Figure 5C), indicating apoptosis may not account for
the decrease in primitive hematopoietic cells in the aGVHD
BM. Thus, our results demonstrate that HSCs were kept in a
more quiescent state, and neither an altered homing process
nor apoptosis contributed to the suppressed hematopoiesis
in the aGVHD hosts.
MEP Differentiation Is Blocked in the aGVHD Hosts
We showed dramatic reductions in CMPs and MEPs in
terms of both frequency and absolute number, yet there was
a concomitant increase in GMPs (Figure 3E,F). Further anal-
ysis showed that the ratio of MEPs to CMPs was signiﬁcantly
lower among the aGVHD CD45.1þ BM cells than among the
control BM cells, suggesting that a blockage may exist in cell
differentiation toward MEPs (Figure 6A). To elucidate the
mechanism, we ﬁrst examined the levels of apoptosis of
CD45.1þ MEPs in the experimental and control groups but
found no signiﬁcant difference (Figure 6B).Figure 4. In vitro colony assay and in vivo cBMT of donor-derived (CD45.1þ) cells. T
hematopoietic cells (CD45.1þ) were sorted for in vitro colony assays. For the CFC a
dium supplemented with a cytokine cocktail. CFU-E, BFU-E, CFU-G, CFU-M, CFU-GM
CFC-monocyte, CFC-granulocyte and monocyte, and CFC-mix (more than 2 lineages
(n ¼ 4 per each group, t-test). The hematopoietic regeneration of donor-derived hema
recipients using the cBMT assay, in which equal numbers of test (CD45.1þ) and co
(CD45.2þ). The overall reconstitution levels of donor-derived HSCs in the primary recip
of the engrafted cells was analyzed 6 months after cBMT (C). Mac-1, B220, and CD
respectively. The results are shown as mean  SE. **P < .01 (n ¼ 3-5 per each group, tOn day 14 after BMT, we collected CD45.1þ CMPs and
analyzed them with quantitative reverse transcriptase PCR.
The expression levels of transcriptional factors essential for
MEP differentiation [31], including c-MPL (CD110), RUNX1,
and CCND1, were signiﬁcantly decreased in CMPs isolated
from the aGVHD hosts compared with the levels in CMPs
isolated from the controls. Quantitative reverse transcriptase
PCR analysis of c-MPL, a negative regulator of MEP differen-
tiation, showed that its expression level was 1.5-fold lower in
the CD45.1þ CMPs, if not LT-HSC, from the aGVHD BM than in
the cells from the control BM (Figure 6C,D). These results
suggest that the differentiation blockage may occur at the
CMP level. The differential expression of these transcription
factors may contribute to the underlying molecular basis of
the blockage of the differentiation of CMPs into MEPs.
CsA Attenuates the Hematopoietic Suppression and
Differentiation Blockage in aGVHD Hosts
We found that the serum levels of Th1 cytokines, including
IL-1a, IL-2, and IFN-g, were signiﬁcantly higher in the aGVHD
mice than in control mice (Supplemental Figure 4). Because
elevated Th1 cytokine levels are a key indicator of donor T
lymphocyte proliferation and differentiation, we investigated
whether inhibiting T cell immunity could attenuate the he-
matopoietic suppression associated with aGVHD. It has been
reported that CsA can inhibit the activity of allo-reactive CD8þ
Tcells [32] and that human graft-versus-host reactions can be
effectively prevented by the administration of CsA [33-36]We
thus administered CsA to the aGVHD mice to determine
whether it can rescue the BM suppression or restore the
quantity of donor-derived HSCs.
After the daily injection of CsA (10 mg/kg) from day 0 to
day 28 (Figure 7A), all mice in the CsA group remainedwo weeks after BMT, mice were killed and BM harvested. The donor-derived
ssay, the sorted CD45.1þ cells were cultured in deﬁned methylcellulose me-
, and CFU-Mix represent CFU-erythrocyte, BFU-erythrocyte, CFC-granulocyte,
), respectively (A). The results are shown as mean  SE. *P < .05; **P < .01
topoietic cells (CD45.1þ) in aGVHD or control mice was examined in secondary
mpetitor cells (CD45.2þ) were cotransplanted into lethally irradiated CB6F1
ients were monitored for 6 months after cBMT (B). Multilineage differentiation
3 were used as markers of myeloid (Mac-1þ), B (B220þ) and T (CD3þ) cells,
-test). The data shown are representative of 3 experiments with similar results.
Figure 5. Homing, apoptosis, and cell cycle of primitive hematopoietic cells in aGVHD BM. As illustrated in Figure 1A, 5  106 BMNCs from B6.SJL mice were
transplanted into lethally irradiated recipients along with 6  107 spleen cells from C57BL/6 mice or CB6F1 mice. (A) In vivo homing assay. At the 16-hour time point,
BMNCs were harvested and stained with CD45.1-FITC and CD45.2-PE. The homing efﬁciency was calculated with the equation CD45.1þ/(CD45.1þþCD45.2þ). %. The
results are shown as mean  SE. P > .05 (n ¼ 5 per each group, t-test). (B) At day 14 after BMT, BMNCs were harvested and stained with anti-Ki67 and Hoechst 33342.
The quantiﬁcation of the G2 þ S/M phase and G0/G1phase cell percentages in the CD45.1þLinSca1þCD150þ subpopulation indicated more quiescent
CD45.1þLinSca1þCD150þ cells in aGVHD animals. The results were obtained from 3 independent experiments. Each value is mean  SE. *P < .05; **P < .01 (n ¼ 5-8
per each group, t-test). (C) Percentages of apoptotic (Annexin Vþ/7-AAD) cells among the CD45.1þ HSCs (LinSca-1þCD150þ), MPP (LinSca-1þ) and HPC (Lin)
subsets at day 14 after BMT are shown. Results are shown as mean  SE. All P > .05 (n ¼ 3-5 per each group, t-test). Data shown are representative of 3 experiments
with similar results.
Y. Lin et al. / Biol Blood Marrow Transplant 20 (2014) 1290e1300 1297healthy and active 5 weeks after BMT, whereas all mice in the
aGVHD group became overtly ill at day 14 after allo-BMT and
died within 4 weeks from exhaustion. Furthermore, daily
injections of CsA prevented the decrease in BM cellularity
(Supplemental Figure 5). The BM cellularity was increased
by 2.0-fold, and B lymphopoiesis was also rescued with
decreased apoptosis after CsA administration (Figure 7B).
The populations of LKS and LKS cells were also recov-
ered. At day 14 after CsA administration, the absolute
numbers of LKS and LKS cells in the CsA-treated mice were
1.97-fold and 1.51-fold higher than those in the aGVHD
group, respectively (Figure 7C). Further analysis of the MEP
and CMP subsets revealed that the frequency of MEPs wasFigure 6. Blockage of differentiation in the hematopoietic hierarchy in aGVHD hosts.
day 14 after BMT, **P ¼ .0015 (n ¼ 10 per each group, t-test). (B) The percentage o
measured at day 14 after BMT. P ¼ .5924 (n ¼ 3, control; n ¼ 11, aGVHD; t-test). (C an
HSCs and analyzed for the expression of c-MPL, RUNX1, CCND1, and FOXO3a by quantit
values of the fold change in expression for 3 independent samples in the aGVHD gr
CD45.1þ CMPs: c-MPL, *P ¼ .0127; RUNX1, **P ¼ .0001; CCND1, **P ¼ .0009; FOXO3a
P ¼ .0713; FOXO3a, P ¼ .1096 (n ¼ 3 per each group, t-test). The data shown are reprincreased by 5-fold, 0.1& versus 0.5&, P< .001 (Figure 7D,E),
by CsA administration, and this increasewas accompanied by
an increase in the ratio of MEPs to CMPs from .24 to .42,
P ¼ .0074 (Figure 7F), indicating that the administration of
CsA can partially reverse the blockage of MEP differentiation
in mice with aGVHD.
DISCUSSION
Previous studies have shown that BM suppression occurs
in addition to alterations in the microenvironment during
aGVHD pathogenesis [28,37]. Although these studies clearly
demonstrated the occurrence of myelosuppression during
aGVHD, they were limited to the analysis of terminally(A) The ratio of MEPs to CMPs within the CD45.1þ population was measured at
f apoptotic (Annexin Vþ/7-AAD) cells among the CD45.1þ MEP subset was
d D) A sample of RNA was extracted from sorted CD45.1þ CMPs or CD45.1þ LT-
ative reverse transcriptase PCR. The bar graphs present the averages of the log
oup compared with those of control mice. Results are shown as mean  SE.
, *P ¼ .0329; CD45.1þ LT-HSCs: c-MPL, P ¼ .0602; RUNX1, P ¼ .2565; CCND1,
esentative of 3 experiments with similar results.
Figure 7. Attenuation of the hematopoietic suppression and differentiation blockage in aGVHD hosts by CsA. The haplo-MHC-matched aGVHD model was established
as above (Figure 1A). The mice in the CsA group received CsA at 10 mg/kg/d from day 0 to day 28 intraperitoneally. Then, the mice were killed at the indicated time
points, and the donor-derived CD45.1þ cells in the BM were analyzed (A). The percentage of apoptotic CD45.1þ B cells (Annexin Vþ/7AAD) was measured at day 14
and day 21 after BMT in mice treated with or without CsA (B). **P < .01 (n ¼ 3 per each group, t-test). The absolute numbers of LKS cells and LKS cells among the
CD45.1þ BMNCs in the 2 groups were measured at day 14 after BMT as shown in the graph (C). LKS: *P ¼ .024, LKS:*P ¼ .0191 (n ¼ 3 per each group, t-test). (D)
Representative ﬂow cytometric analysis of CMPs, GMPs, and MEPs in the donor-derived CD45.1þ population at day 14 after BMT with or without CsA. The frequencies
of MEPs in CD45.1þ cells and the ratios of MEPs to CMPs at day 14 after BMT in aGVHD mice with or without CsA are shown in the graphs (E and F). Frequencies of
MEPs: *P < .001 (n ¼ 8 per each group, t-test); MEP/CMP: P ¼ .0074 (n ¼ 8 per each group, t-test). The data shown are representative of 4 experiments with similar
results.
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this process was not documented in detail. Our data indicate
that the cytopenia observed in our model can be largely
attributed to the suppression of HSPCs and defective differ-
entiation into certain lineages, such as B cells and MEPs,although the altered microenvironment and other factors
may also contribute to this process. HSCs were kept quiescent
in the presence of aGVHD stress but did not have an altered
homing ability. Although the absolute number of HSCs was
decreased, their self-renewal ability remained intact.
Y. Lin et al. / Biol Blood Marrow Transplant 20 (2014) 1290e1300 1299Our previous work showed that normal HSCs recovered
from T leukemic hosts were still highly functional after
being seeded into a nonleukemic host [10]. The similarity of
the performance of HSCs in these 2 studies is due to the ar-
rest of the cell cycle under stress [10]. Indeed, cell cycle arrest
is a protective mechanism and a common cellular response
to stress [8,10,38]. Therefore, when more-quiescent HSCs
from aGVHD hosts are seeded into a new host, these cells
reenter the cell cycle, and the self-renewal potential of the
HSCs can be fully restored (Figure 4B).
Our study thus establishes a link between HSPCs and
thrombocytopenia in aGVHD, a previously unappreciated
connection. Prolonged thrombocytopenia is a frequent
complication after allo-HSC transplantation. A low platelet
count on the 60th day after transplantation has been shown
to be an independent risk factor for poor prognosis in allo-
HSC transplantation patients [39]. Other studies have
linked poor prognoses to thrombocytopenia 100 days after
allo-BMT [4,40]. The major causes of thrombocytopenia
include accelerated peripheral platelet destruction by anti-
platelet antibodies and the insufﬁcient production of plate-
lets from marrow megakaryocytes; the latter mechanism
may play a predominant role [41,42]. In the present study, we
found that during aGVHD, the CMP subset was signiﬁcantly
decreased and there was a blockage in differentiation to
MEPs. Consequently, GMPs were increased and correlated
with the augmented levels of granulocytes and monocytes in
the PB (Figure 2F,G). Changes to the CMP subset were asso-
ciated with cell cycle arrest and growth suppression of the
HSC pool. These results are further supported by the in vitro
functional characterization of HSPCs (Figure 4A).
Consistent with the ﬁnding of decreased MEPs in aGVHD
BM, CMPs from aGVHD mice had signiﬁcant lower expres-
sion levels of c-MPL, an important regulator of the develop-
ment of megakaryocytes and platelets (Figure 6C,D). C-Mpl
(CD110), which is expressed on the surfaces of megakaryo-
cytes and megakaryocyte precursors, is a receptor for
thrombopoietin (TPO). Yamazaki et al. [42] found that
plasma TPO was signiﬁcantly increased in HSC transplant
recipients with thrombocytopenia in comparison with those
without; however, no study has focused on c-Mpl (CD110)
expression in megakaryocytes in allo-HSC transplantation
context. Although we did not measure TPO status in aGVHD
hosts, we found the primitive hematopoietic subset was
unresponsive to TPO, resulting in signiﬁcantly fewer CFU
megakaryocytes derived from CD45.1þ cells isolated from
aGVHD BM in vitro, which aggravated the thrombocytopenia
(data not shown).
The secretion of the inﬂammatory cytokines IL-1a, IL-2,
and IFN-g is closely related with expansion of donor CD8þ
T cells in the early stage of aGVHD, as shown in previous
studies [21,43]. Evolving inﬂammatory cytokines disrupt
the BM structure, which may interfere with the physio-
logical interactions between HSCs and their niches. Inter-
estingly, when the aGVHD hosts were treated with CsA, the
frequencies and function of HSPCs were partially restored.
These effects could be primarily due to the suppressive
effect of CsA on the expansion of allo-reactive CD8þ T cells.
A previous study by Shono et al. [28] showed that the
impaired BM stroma and osteoblasts cannot support he-
matopoiesis in aGVHD hosts, and the present study pro-
vides the immune cues for the hematopoietic cues.
Therefore, the actual effects of the aGVHD environment on
normal tissue stem cells are most likely the result of
multiple factors, including the model and stage of aGVHD,the conditioning regimen, and even the deﬁned phenotype
of primitive hematopoietic cells. Our model underscores
the importance of the immune environment or conditions
in dictating the speciﬁc functional state of tissue stem
cells. Because CsA can only partially restore the BM cellu-
larity in aGVHD hosts, it is possible that other factors
may contribute to the inhibition of HSPCs and MEP
differentiation.
Taken together, our study demonstrates for the ﬁrst time
that the pathological condition of aGVHD may negatively
affect HSPCs. The resulting hematopoietic suppression,
especially the blocked differentiation or commitment along
B cells or megakaryopoietic/erythropoietic lineage, may
ultimately cause cytopenia. Interestingly, these abnormal-
ities can be partially improved by the administration of
CsA, an effective agent for managing aGVHD in patients.
However, caution must be taken before these ﬁndings can
be generalized and applied to humans, especially in the
situationwhereMHC-matched donors are used. Our current
ﬁndings might be more relevant to the haplo-BMT for
patients.
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